Related Experiment Video

Updated: Jul 8, 2026

Screening Ion Channels in Cancer Cells
06:19

Screening Ion Channels in Cancer Cells

Published on: June 16, 2023

Potassium channels are a new target field in anticancer drug design

Nuria Villalonga1, Joan C Ferreres, Josep M Argilés

  • 1Molecular Physiology Laboratory, Departament de Bioquímica i Biologia Molecular de la Facultat de Biologia, Universitat de Barcelona.

Recent Patents on Anti-Cancer Drug Discovery
|January 29, 2008
PubMed

Insights

Potassium channels are crucial for cell function and are implicated in cancer cell proliferation. Targeting these channels presents a promising avenue for novel cancer treatment strategies.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Potassium channels are a diverse family of membrane proteins regulating membrane potential and various physiological processes.
  • Dysregulated potassium channel expression is observed in cancer cells, correlating with malignancy grade.
  • Potassium channel activity impacts cell proliferation and cell-cycle progression.

Purpose of the Study:

  • To review the role of potassium channels in tumor cell proliferation.
  • To highlight the potential of targeting potassium channels for cancer therapy.
  • To discuss recent patents related to potassium channels in cancer treatment.

Main Methods:

  • Literature review of scientific publications.
  • Analysis of recent patent filings.
  • Synthesis of existing research on potassium channels and cancer.

Main Results:

  • Potassium channels are involved in key cellular processes relevant to cancer.
  • Impaired expression of certain potassium channels is a hallmark of various tumors.
  • Inhibition of potassium channel activity can impede cancer cell proliferation.

Conclusions:

  • Potassium channels play a significant role in tumor cell proliferation.
  • These channels represent viable therapeutic targets for developing new anti-cancer drugs.
  • Emerging patents underscore the therapeutic potential of targeting potassium channels in oncology.

More Related Videos

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels10:07

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

A Fluorescent Screening Assay for Identifying Modulators of GIRK Channels05:31

A Fluorescent Screening Assay for Identifying Modulators of GIRK Channels

Published on: April 24, 2012

Related Concept Videos

Non-gated Ion Channels01:24

Non-gated Ion Channels

Ion channels are specialized proteins on the plasma membrane that allow charged ions to pass down their electrochemical gradient. Their main function is to maintain the membrane potential which is critical for cell viability. These channels are either gated or non-gated and can transport more than a thousand ions within milliseconds for the cellular event to occur.
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism.
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...